---
title: Oral Amantadine Versus Gabapentin to Attenuate the Response to Laryngoscopy and Tracheal Intubation
nct_id: NCT03172234
overall_status: COMPLETED
phase: PHASE2, PHASE3
sponsor: Ghada Mohammed AboelFadl
study_type: INTERVENTIONAL
primary_condition: Effect of Laryngoscopy and Tracheal Intubation
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03172234.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03172234"
ct_last_update_post_date: 2018-09-25
last_seen_at: "2026-05-12T06:35:38.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Oral Amantadine Versus Gabapentin to Attenuate the Response to Laryngoscopy and Tracheal Intubation

**Official Title:** Oral Amantadine Versus Gabapentin to Attenuate the Hemodynamic Response to Laryngoscopy and Tracheal Intubation and Their Effect on β-endorphin

**NCT ID:** [NCT03172234](https://clinicaltrials.gov/study/NCT03172234)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 90
- **Lead Sponsor:** Ghada Mohammed AboelFadl
- **Conditions:** Effect of Laryngoscopy and Tracheal Intubation
- **Start Date:** 2017-06-15
- **Completion Date:** 2018-05-15
- **CT.gov Last Update:** 2018-09-25

## Brief Summary

To evaluate the effect of oral amantadine versus gabapentin premedication on the hemodynamic response to laryngoscopy and tracheal intubation and their effect on β-endorphins.

## Detailed Description

Direct laryngoscopy and passage of endotracheal tube through the larynx is a noxious stimulus, which can provoke untoward response in the cardiovascular, respiratory and other physiological systems. Gabapentin, is 1-aminomethyl cyclohexane acetic acid.Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA). Gabapentin act in central nervous system CNS), it acts by decreasing the synthesis of neurotransmitter glutamate and by binding to the alpha 2 delta subunits of voltage dependent calcium channels.

Amantadine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, and compared to ketamine, it is well tolerated with fewer side effects (mainly dizziness, sedation, and dry mouth). Amantadine's formulation permits the oral route for drug delivery, as well as the IV route. The side-effects profile of amantadine via all routes seems not to be harmful in appropriate dosages.. Amantadine has been clinically used as an antiviral drug, for dementia, and in the treatment of Parkinson's disease and spasticity. It is a non-competitive NMDA receptor antagonist, and compared to ketamine, it is well tolerated with fewer side effects (mainly dizziness, sedation, and dry mouth). Amantadine's formulation permits the oral route for drug delivery, as well as the IV route. The side-effects profile of amantadine via all routes seems not to be harmful in appropriate dosages.

In the central nervous system, beta-endorphins bind mu-opioid receptors and exert their primary action at presynaptic nerve terminals. However, instead of inhibiting substance P, they exert their analgesic effect by inhibiting the release of GABA, an inhibitory neurotransmitter, resulting in excess production of dopamine.

The investigators designed this study to prove the efficacy of oral amantadine versus gabapentin premedication on the hemodynamic response to laryngoscopy and tracheal intubation and their effect on β-endorphins.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* ASA I\&II scheduled for elective spine surgery

Exclusion Criteria:

* Patient refusal
* Patients with ASA score III (with chronic kidney, lungs, Gastrointestinal tract, liver, or cardiovascular diseases)
* Pregnant or breastfeeding women.
* Allergy to any of the study medications and taking medications that could significantly interact with amantadine (tramadol, atropine, antipsychotic medications)
* diabetes mellitus, thyroid disease any endocrine disease
* Suspected difficult intubation or intubation time more than 30 second.
```

## Arms

- **amantadine group (Group A)** (ACTIVE_COMPARATOR) — the patients will receive oral amantadine sulfate using the dose 100 mg 120 minutes prior to the surgery, 5 ml saline IV 5 minutes before intubation.
- **gabapentin group(Group B)** (ACTIVE_COMPARATOR) — the patients will receive oral gabapentin using the dose 800 mg 120 minutes prior to surgery,5 ml saline IV 5 minutes before intubation.
- **control group (group C)** (PLACEBO_COMPARATOR) — the patients will receive placebo oral tablet 120 minutes prior to surgery, IV fentanyl 2µ/kg in 5 ml saline 5 minutes before intubation.

## Interventions

- **oral amantadine sulfate** (OTHER) — In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
- **oral gabapentin** (DRUG) — In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
- **Placebo Oral Tablet** (DRUG) — in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery

## Primary Outcomes

- **effect of oral amantadine versus gabapentin premedication on laryngoscopy and tracheal intubation on β-endorphins.** _(time frame: baseline blood sample taken before drug administration and after 15 minutes after intubation and before skin incision)_ — analysis of change of β-endorphins in blood sample

## Secondary Outcomes

- **effect of oral amantadine versus gabapentin premedication on the Mean arterial blood pressure due to laryngoscopy and tracheal intubation** _(time frame: baselineMAP before drug administration and after 15 minutes after intubation and before skin incision)_
- **effect of oral amantadine versus gabapentin premedication on the heart rate due to laryngoscopy and tracheal intubation** _(time frame: baseline heart rate before drug administration and after 15 minutes after intubation and before skin incision)_

## Locations (1)

- Assiut university hospitals, Asyut, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.assiut university hospitals|asyut||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03172234.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03172234*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*